Macquarie Group
ADVM

Macquarie Group’s Adverum Biotechnologies ADVM Stock Holding History

Macquarie Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,586
Closed -$37 – 1894
2024
Q1 		$37 Buy
+2,586
New +$39.3K ﹤0.01% 1659
2021
Q4 		– Sell
-171
Closed -$4K – 2594
2021
Q3 		$4K Hold
171
– – ﹤0.01% 2604
2021
Q2 		$6K Hold
171
– – ﹤0.01% 2512
2021
Q1 		$17K Sell
171
-51
-23% -$6.12K ﹤0.01% 2316
2020
Q4 		$24K Hold
222
– – ﹤0.01% 2181
2020
Q3 		$23K Hold
222
– – ﹤0.01% 2134
2020
Q2 		$46K Buy
+222
New +$39.3K ﹤0.01% 1953
2018
Q1 		– Sell
-240
Closed -$8K – 2154
2017
Q4 		$8K Buy
+240
New +$7.9K ﹤0.01% 2297

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Macquarie Group's ADVM Position: Q2 2024 in Review

Macquarie Group sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 2,586 shares — an estimated $37 sold.

Macquarie Group first reported a position in ADVM in Q4 2017 and held it in 8 quarters. The position peaked at $46K in Q2 2020. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

  • Macquarie Group reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 2,586 Adverum Biotechnologies shares in Q2 2024, an estimated $37.
  • Macquarie Group first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 8 quarters.
  • Macquarie Group's Adverum Biotechnologies position peaked at $46K in Q2 2020.
  • 68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.